BioWorld

May 6, 2005

Cephalon's Oravescent Fentanyl Hits Primary Endpoint In Phase III

In reporting positive results from a Phase III study of Oravescent fentanyl, Cephalon Inc. said it is on track to submit a new drug application to the FDA next quarter. (BioWorld Today) Read More

Bayhill Therapeutics Raises $35M In Series B For Autoimmune Drugs

Ironies Abound In Science, Tetrahydrocannabinol Rules

Avidia Advancing Lead Product Through $28.5M Series B Round

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 6, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis

BioWorld Science

Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...